Aire Advisors LLC Has $1.98 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Aire Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 2.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 13,573 shares of the company’s stock after selling 356 shares during the quarter. Aire Advisors LLC’s holdings in Johnson & Johnson were worth $1,984,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Chilton Capital Management LLC lifted its stake in shares of Johnson & Johnson by 5.0% in the second quarter. Chilton Capital Management LLC now owns 17,517 shares of the company’s stock valued at $2,560,000 after buying an additional 839 shares in the last quarter. Rockline Wealth Management LLC boosted its holdings in Johnson & Johnson by 3.0% during the second quarter. Rockline Wealth Management LLC now owns 27,611 shares of the company’s stock worth $4,036,000 after purchasing an additional 808 shares during the last quarter. Harfst & Associates Inc. grew its position in Johnson & Johnson by 2.5% in the 2nd quarter. Harfst & Associates Inc. now owns 12,936 shares of the company’s stock worth $1,891,000 after purchasing an additional 318 shares in the last quarter. Verus Capital Partners LLC increased its stake in Johnson & Johnson by 27.2% in the 2nd quarter. Verus Capital Partners LLC now owns 7,244 shares of the company’s stock valued at $1,059,000 after buying an additional 1,551 shares during the last quarter. Finally, Convergence Investment Partners LLC lifted its position in shares of Johnson & Johnson by 54.5% during the 2nd quarter. Convergence Investment Partners LLC now owns 13,811 shares of the company’s stock worth $2,019,000 after buying an additional 4,871 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $167.16 on Wednesday. The firm has a 50 day moving average of $156.42 and a 200-day moving average of $153.60. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $402.30 billion, a P/E ratio of 10.42, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $167.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period in the previous year, the business earned $2.80 EPS. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on JNJ shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 30th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. The Goldman Sachs Group cut their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. TD Securities decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Tuesday. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.